Syn-Tech Chem & Pharm Co (ROCO:1777) Current Deferred Revenue: NT$4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1777 Syn-Tech Chem & Pharm Co Ltd ROCO:1777
81 GF Score
Price NT$74.30
GF Value NT$97.21
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Syn-Tech Chem & Pharm Co Current Deferred Revenue?

Syn-Tech Chem & Pharm Co ROCO:1777 +0.54% 81 Current Deferred Revenue is NT$4 Mil as of Jun. 2026. GuruFocus rates ROCO:1777 with a GF Score™ of 81/100 and a GF Value™ of NT$97.21 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Syn-Tech Chem & Pharm Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$4 Mil.

Syn-Tech Chem & Pharm Co Current Deferred Revenue Related Terms

Syn-Tech Chem & Pharm Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Syn-Tech Chem & Pharm Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn-Tech Chem & Pharm Co Current Deferred Revenue Chart

Syn-Tech Chem & Pharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 0.02 0.03 4.75 1.93

Syn-Tech Chem & Pharm Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 1.87 1.93 2.79 3.56
ROCO:1777
81GF Score
Syn-Tech Chem & Pharm Co Ltd ROCO:1777
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$4 Mil mean?
Syn-Tech Chem & Pharm Co (ROCO:1777) has a Current Deferred Revenue of NT$4 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Syn-Tech Chem & Pharm Co and its competitors.
Is Syn-Tech Chem & Pharm Co's Current Deferred Revenue too high?
Syn-Tech Chem & Pharm Co's current Current Deferred Revenue is NT$4 Mil. Overall, Syn-Tech Chem & Pharm Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syn-Tech Chem & Pharm Co's Current Deferred Revenue compare to VRTX and REGN?
Syn-Tech Chem & Pharm Co's Current Deferred Revenue of NT$4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Syn-Tech Chem & Pharm Co and its competitors. Syn-Tech Chem & Pharm Co's current Current Deferred Revenue is NT$4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn-Tech Chem & Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co (ROCO:1777) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$97.21, compared to a current price of NT$74.30 — trading 23.6% below its estimated fair value. The current Current Deferred Revenue is NT$4 Mil. Syn-Tech Chem & Pharm Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Syn-Tech Chem & Pharm Co (ROCO:1777), the current Current Deferred Revenue is NT$4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syn-Tech Chem & Pharm Co (ROCO:1777) Overvalued in 2026?

Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co stock appears to be undervalued. The current stock price of NT$74.30 is trading 23.6% below its estimated GF Value™ of NT$97.21. GuruFocus considers Syn-Tech Chem & Pharm Co to be Modestly Undervalued.

Key valuation signals for ROCO:1777:

  • Current Deferred Revenue: NT$4 Mil
  • GF Value™: NT$97.21 vs. price of NT$74.30 (23.6% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the ROCO:1777 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syn-Tech Chem & Pharm Co Business Description

Address No. 168, Kai Yuan Road, Xinying District, Tainan City, TWN, 73055
Syn-Tech Chem & Pharm Co Ltd is a Taiwanese manufacturer of active pharmaceutical ingredients (APIs) and finished pharmaceutical products. The company develops and produces APIs for generic drugmakers, pharmaceutical companies, and trading agents, with a product portfolio that includes Alfuzosin HCl, Atomoxetine HCl, Chlorzoxazone, Cloperastine HCl, Crotamiton, and Diclofenac Epolamine, among others. In addition to human medicines, it manufactures veterinary drugs, food additives, and cosmetics. Its customer base consists primarily of domestic and international pharmaceutical manufacturers and distributors. Geographically, the company serves markets across Asia, Europe, and the Americas, generating the majority of its revenue from Asian markets outside Taiwan. Its business model centers on the contract development and manufacture of pharmaceutical ingredients and finished dosage forms, supplemented by sales of specialty chemicals and related products.
81GF Score

Get the complete analysis for ROCO:1777

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.30
Price
NT$97.21
GF Value